{"answer":{"query":"farxiga","resolved_as":"name","packages":17,"applications":["NDA202293"],"identity":{"application_numbers":["NDA202293"],"marketing_categories":["NDA","NDA AUTHORIZED GENERIC"],"labelers":[{"text":"E.R. SQUIBB & SONS, LLC.","untrusted":true},{"text":"ASTRAZENECA PHARMACEUTICALS LP","untrusted":true},{"text":"PRASCO LABORATORIES","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED","untrusted":true}],"marketing_start":{"earliest":"2015-01-05","latest":"2024-03-18","packages_with_a_start_date":7}},"price":{"median_negotiated_over_nadac":0.501,"packages_compared":5,"packages_listed":17,"negotiated_price_ends":null,"rows":[{"ndc":"00003142711","name":{"text":"Farxiga","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142712","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142713","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142714","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142791","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142811","name":{"text":"Farxiga","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142812","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142813","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142814","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00003142891","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":null},{"ndc":"00310620530","name":{"text":"Farxiga 5mg 30 CT Bottle","untrusted":true},"class":"B","nadac_per_unit":12.07465,"negotiated_per_unit":6.052894,"ratio":0.501,"ful_per_unit":null},{"ndc":"00310620590","name":{"text":"FARXIGA TAB 5MG BT 1X90 EA US","untrusted":true},"class":"B","nadac_per_unit":12.07465,"negotiated_per_unit":6.052894,"ratio":0.501,"ful_per_unit":null},{"ndc":"00310621030","name":{"text":"Farxiga 10MG 30CT","untrusted":true},"class":"B","nadac_per_unit":12.07647,"negotiated_per_unit":6.052894,"ratio":0.501,"ful_per_unit":null},{"ndc":"00310621039","name":{"text":"FARXIGA TAB 10MG HUD BL 3X10 EA US","untrusted":true},"class":"B","nadac_per_unit":12.07647,"negotiated_per_unit":6.052894,"ratio":0.501,"ful_per_unit":null},{"ndc":"00310621090","name":{"text":"FARXIGA TAB 10MG BT 1X90 EA US","untrusted":true},"class":"B","nadac_per_unit":12.07647,"negotiated_per_unit":6.052894,"ratio":0.501,"ful_per_unit":null},{"ndc":"66993045630","name":{"text":"Dapagliflozin Tablets 5 mg, 30","untrusted":true},"class":"G","nadac_per_unit":0.16313,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":0.487667,"ratio_note":"generic package: not compared with the brand negotiated price"},{"ndc":"66993045730","name":{"text":"Dapagliflozin Tablets 10 mg, 30","untrusted":true},"class":"G","nadac_per_unit":0.18445,"negotiated_per_unit":6.052894,"ratio":null,"ful_per_unit":0.530268,"ratio_note":"generic package: not compared with the brand negotiated price"}],"negotiated_scheduled":{"thirty_day":183.33,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA202293","date":"2041-10-01","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"12213988*PED","productNo":"002"},"latest_patent_expiry":"2041-10-01","latest_exclusivity_expiry":"2027-12-12","dated_barriers":64,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":17,"exclusivities_listed":4,"fact_id":"ac32a0138e0f438f251f8dbd"}],"label_history":{"events_total":23,"non_cmc_events":20,"counts_by_class":{"LABELING":12,"EFFICACY":8},"cmc_events":3,"recent_non_cmc_events":[{"application":"NDA202293","submission_no":35,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-06-03","documents":[{"type":"Letter","date":"2026-06-05","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/202293Orig1s035ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-06-09","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202293s035lbl.pdf","untrusted":true}}],"fact_id":"6a14d926781e3b203435a164"},{"application":"NDA202293","submission_no":31,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2024-06-12","documents":[{"type":"Letter","date":"2024-06-13","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/202293Orig1s031,205649Orig1s022ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-06-13","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202293s031lbl.pdf","untrusted":true}}],"fact_id":"b33f03c4c3851c837bea7ec2"},{"application":"NDA202293","submission_no":30,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-09-12","documents":[{"type":"Letter","date":"2023-09-13","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/202293Orig1s030;205649Orig1s021ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-09-13","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s030lbl.pdf","untrusted":true}}],"fact_id":"f0eb2a65d168741bbee62de7"},{"application":"NDA202293","submission_no":26,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2023-05-08","documents":[{"type":"Label","date":"2023-05-09","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s026lbl.pdf","untrusted":true}},{"type":"Letter","date":"2023-05-09","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/202293Orig1s026ltr.pdf","untrusted":true}}],"fact_id":"0eb5752e1936913310dadf32"},{"application":"NDA202293","submission_no":27,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-02-17","documents":[{"type":"Letter","date":"2023-01-05","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/202293Orig1s027ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-01-09","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293Orig1s027lbl.pdf","untrusted":true}}],"fact_id":"db3d922576685e59068214f2"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":2,"te_code_counts":{"AB":2},"marketing_status_counts":{"Prescription":2},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA202293","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"FARXIGA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"10MG","untrusted":true}},{"application":"NDA202293","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"FARXIGA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"5MG","untrusted":true}}]},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":2,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"DAPAGLIFLOZIN","untrusted":true},"recruiting_interventional_count":98,"not_yet_recruiting_count":45,"by_phase":{"PHASE4":32,"PHASE3":28,"EARLY_PHASE1":1,"PHASE2":18,"NA":10,"PHASE2/PHASE3":4,"PHASE1":4,"PHASE1/PHASE2":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT06742723","title":{"text":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"AstraZeneca","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2025-03-03","link":{"text":"https://clinicaltrials.gov/study/NCT06742723","untrusted":true}},{"nct_id":"NCT07323524","title":{"text":"Dapagliflozin in Active Lupus Nephritis","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Brigham and Women's Hospital","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2026-05-22","link":{"text":"https://clinicaltrials.gov/study/NCT07323524","untrusted":true}},{"nct_id":"NCT07235280","title":{"text":"Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma","untrusted":true},"phase":["EARLY_PHASE1"],"sponsor":{"text":"Jonsson Comprehensive Cancer Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2025-12-02","link":{"text":"https://clinicaltrials.gov/study/NCT07235280","untrusted":true}},{"nct_id":"NCT07351643","title":{"text":"CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Shenyang Northern Hospital","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-30","start_date":"2026-06-25","link":{"text":"https://clinicaltrials.gov/study/NCT07351643","untrusted":true}},{"nct_id":"NCT07662109","title":{"text":"A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"AstraZeneca","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-30","start_date":"2026-07-06","link":{"text":"https://clinicaltrials.gov/study/NCT07662109","untrusted":true}}],"fact_id":"7fb5e28dc89a618297d757a9"}]},"spending":{"reported_under":{"generic":{"text":"Dapagliflozin Propanediol","untrusted":true},"brand":{"text":"Farxiga","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":736787563.52,"claims":858348,"beneficiaries":193920,"average_spending_per_claim_usd":858.37861045,"fact_id":"a320b6b3107d6f483e9e83ed"},{"year":2021,"gross_spending_usd":1421505274.4,"claims":1540905,"beneficiaries":385693,"average_spending_per_claim_usd":922.51324672,"fact_id":"c5a501462638e6063477d9d3"},{"year":2022,"gross_spending_usd":2584621149.6,"claims":2665029,"beneficiaries":638800,"average_spending_per_claim_usd":969.82852705,"fact_id":"b0b61ee2ed475e88a6347140"},{"year":2023,"gross_spending_usd":4342182307.3,"claims":4298827,"beneficiaries":993909,"average_spending_per_claim_usd":1010.0853808,"fact_id":"6189976c018d32383fb7a218"},{"year":2024,"gross_spending_usd":5290548963.4,"claims":5634650,"beneficiaries":1269216,"average_spending_per_claim_usd":938.93124922,"fact_id":"731a2f17639450ebdaef63d7"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"medicaid_state_utilization":{"year":2025,"states_with_data":36,"all_states_medicaid_reimbursed_usd":50312213.31,"all_states_medicaid_paid_prescriptions":62530,"top_states":[{"state":"CA","medicaid_paid_prescriptions":8485,"medicaid_reimbursed_usd":11584537.52,"total_reimbursed_usd":11721479.24,"packages":2,"covers":"fee_for_service_only","fact_id":"9e4cf1d33e69611f6247e1a4"},{"state":"NY","medicaid_paid_prescriptions":11582,"medicaid_reimbursed_usd":10250979.88,"total_reimbursed_usd":10267225.47,"packages":4,"covers":"fee_for_service_only","fact_id":"77631026f11d9e357007930b"},{"state":"TX","medicaid_paid_prescriptions":16007,"medicaid_reimbursed_usd":8430880.88,"total_reimbursed_usd":8533903.3,"packages":2,"covers":"fee_for_service_only","fact_id":"4706901b6fd924da7ca00f2e"},{"state":"OH","medicaid_paid_prescriptions":3732,"medicaid_reimbursed_usd":2855830.43,"total_reimbursed_usd":2871345.38,"packages":2,"covers":"all_record_types","fact_id":"fd22ea7d47be7754edfe84e6"},{"state":"PA","medicaid_paid_prescriptions":2207,"medicaid_reimbursed_usd":1718976.12,"total_reimbursed_usd":1737252.37,"packages":2,"covers":"fee_for_service_only","fact_id":"feda596b4719f3dd1b988608"},{"state":"KY","medicaid_paid_prescriptions":2069,"medicaid_reimbursed_usd":1613664.41,"total_reimbursed_usd":1613664.41,"packages":2,"covers":"fee_for_service_only","fact_id":"37eaaaa1d47e49f235614079"},{"state":"AZ","medicaid_paid_prescriptions":1303,"medicaid_reimbursed_usd":1277320.51,"total_reimbursed_usd":1308289.51,"packages":2,"covers":"fee_for_service_only","fact_id":"68e7310469171aa791a5a625"},{"state":"IL","medicaid_paid_prescriptions":1396,"medicaid_reimbursed_usd":1244143.68,"total_reimbursed_usd":1245713.28,"packages":1,"covers":"fee_for_service_only","fact_id":"391352cc86be21b2f894cf43"},{"state":"WV","medicaid_paid_prescriptions":1742,"medicaid_reimbursed_usd":1064472.91,"total_reimbursed_usd":1090710.58,"packages":2,"covers":"all_record_types","fact_id":"cd76fe6c2f5c109ee9ac4089"},{"state":"IN","medicaid_paid_prescriptions":1392,"medicaid_reimbursed_usd":940806.83,"total_reimbursed_usd":943464,"packages":2,"covers":"fee_for_service_only","fact_id":"0cf33ab2ecb3cd4678956dcf"}],"unlabelled_state_code_xx":{"medicaid_paid_prescriptions":41352,"medicaid_reimbursed_usd":39572993.52,"note":"the source uses the code XX without defining it; it is reported here and never added to a state"},"built_from_facts":61,"facts_fee_for_service_only":27,"older_year_facts_not_used":177,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"507b4ad36642545f27b9ff97","field":"ndc.listing","entity":"ndc:00310620530"},{"fact_id":"18faec14cfd292c48bca1a3d","field":"ndc.listing","entity":"ndc:00310620590"},{"fact_id":"7016b67331298316eb393d7d","field":"ndc.listing","entity":"ndc:00310621030"},{"fact_id":"b48eba36677268e3c33a0002","field":"ndc.mfp","entity":"ndc:00003142711"},{"fact_id":"59fc853ead8032460db28f10","field":"ndc.mfp","entity":"ndc:00003142712"},{"fact_id":"7d206c7ec9ca532b5a73b139","field":"ndc.mfp","entity":"ndc:00003142713"},{"fact_id":"ac32a0138e0f438f251f8dbd","field":"drug.generic_entry_earliest","entity":"application:NDA202293"},{"fact_id":"e88eea72a55bf959a711ede4","field":"drug.patent","entity":"application:NDA202293"},{"fact_id":"73368c15f8b4f56a8d4608f0","field":"drug.exclusivity","entity":"application:NDA202293"},{"fact_id":"6a14d926781e3b203435a164","field":"drug.label_event","entity":"application:NDA202293"},{"fact_id":"b33f03c4c3851c837bea7ec2","field":"drug.label_event","entity":"application:NDA202293"},{"fact_id":"f0eb2a65d168741bbee62de7","field":"drug.label_event","entity":"application:NDA202293"},{"fact_id":"0eb5752e1936913310dadf32","field":"drug.label_event","entity":"application:NDA202293"},{"fact_id":"db3d922576685e59068214f2","field":"drug.label_event","entity":"application:NDA202293"},{"fact_id":"888534e73cba8a95d077d345","field":"drug.te_code","entity":"application:NDA202293"},{"fact_id":"63dc0cd8fd7d7ec11ff40869","field":"drug.marketing_status","entity":"application:NDA202293"},{"fact_id":"2d579f44231238372a265c1e","field":"drug.te_code","entity":"application:NDA202293"},{"fact_id":"6e243ef24ee1b9f63331d76f","field":"drug.marketing_status","entity":"application:NDA202293"},{"fact_id":"7fb5e28dc89a618297d757a9","field":"drug.trial_access","entity":"drug:dapagliflozin"},{"fact_id":"a320b6b3107d6f483e9e83ed","field":"drug.partd_spending","entity":"drug:dapagliflozin-propanediol|farxiga"},{"fact_id":"c5a501462638e6063477d9d3","field":"drug.partd_spending","entity":"drug:dapagliflozin-propanediol|farxiga"},{"fact_id":"b0b61ee2ed475e88a6347140","field":"drug.partd_spending","entity":"drug:dapagliflozin-propanediol|farxiga"},{"fact_id":"6189976c018d32383fb7a218","field":"drug.partd_spending","entity":"drug:dapagliflozin-propanediol|farxiga"},{"fact_id":"731a2f17639450ebdaef63d7","field":"drug.partd_spending","entity":"drug:dapagliflozin-propanediol|farxiga"},{"fact_id":"9e4cf1d33e69611f6247e1a4","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:CA"},{"fact_id":"77631026f11d9e357007930b","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:NY"},{"fact_id":"4706901b6fd924da7ca00f2e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:66993045730:TX"},{"fact_id":"fd22ea7d47be7754edfe84e6","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:OH"},{"fact_id":"feda596b4719f3dd1b988608","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:PA"},{"fact_id":"37eaaaa1d47e49f235614079","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:KY"},{"fact_id":"68e7310469171aa791a5a625","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:AZ"},{"fact_id":"391352cc86be21b2f894cf43","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:IL"},{"fact_id":"cd76fe6c2f5c109ee9ac4089","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:WV"},{"fact_id":"0cf33ab2ecb3cd4678956dcf","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310621090:IN"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"AMBIGUOUS","field":"spending","reason":"2 brand and generic name pairs match; the series shown is the one with the newest year and the largest spending"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}